Loading...
•
Sep 30, 2021
Boston Scientific Q3 2021 Earnings Report
Announced results for the third quarter of 2021, demonstrating revenue growth and improved earnings per share compared to the prior year period.
Key Takeaways
Boston Scientific reported net sales of $2.932 billion for Q3 2021, representing a 10.3% increase on a reported basis and a 10.6% increase on an organic basis. GAAP net income available to common stockholders was $0.28 per share, compared to a net loss of $(0.12) per share in the prior year, with adjusted EPS reaching $0.41. The company's growth strategy and recent acquisitions have positioned it well for long-term success.
Net sales reached $2.932 billion, up 10.3% reported and 10.6% organic.
GAAP EPS was $0.28, compared to $(0.12) in the prior year.
Adjusted EPS was $0.41, compared to $0.37 a year ago.
Completed acquisitions of Lumenis LTD.'s global surgical business and Farapulse, Inc.
Boston Scientific
Boston Scientific
Boston Scientific Revenue by Segment
Boston Scientific Revenue by Geographic Location
Revenue by Segment
MedSurg Revenue
CapyFin.comCardiovascular Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope, Middle East & Africa Revenue
CapyFin.comAsia Pacific Revenue
CapyFin.comLatin America & Canada Revenue
CapyFin.com Forward Guidance
The company estimates net sales growth for the full year 2021 to be in a range of approximately 19 to 20 percent on a reported basis, and approximately 18 to 19 percent on an organic basis. The company estimates net sales growth for the fourth quarter of 2021 to be in a range of approximately 13 to 17 percent on a reported basis, and approximately 12 to 16 percent on an organic basis.
Positive Outlook
- Full year 2021 net sales growth is expected to be in the range of 19-20% on a reported basis.
- Full year 2021 organic net sales growth is projected to be approximately 18-19%.
- Full year 2021 EPS on a GAAP basis is estimated to be in the range of $0.83 to $0.85.
- Full year 2021 adjusted EPS is expected to be $1.60 to $1.62.
- Fourth quarter 2021 net sales growth is anticipated to be 13-17% on a reported basis.
Challenges Ahead
- Fourth quarter 2021 net sales growth to be in a range of approximately 13 to 17 percent on a reported basis
- The company estimates EPS on a GAAP basis in a range of $0.21 to $0.23
- The company estimates adjusted EPS, excluding certain charges (credits), of $0.43 to $0.45.
- Full year organic net sales guidance excludes the impact of foreign currency fluctuations
- Excludes the intrauterine health franchise and the Specialty Pharmaceuticals business, which were divested in Q2 2020 and Q1 2021, respectively.
Revenue & Expenses
Visualization of income flow from segment revenue to net income